AstraZeneca: AstraZeneca's cholesterol pill is set for Phase 3, but lags behind Merck rival

AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believing that it could reach peak sales of more than $5 billion. Positive data presented Monday at the American College of Cardiology meeting bring that ...